These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 6514014

  • 1. The effectiveness of yohimbine in blocking rat central dopamine autoreceptors in vivo.
    van Oene JC, de Vries JB, Horn AS.
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Oct; 327(4):304-11. PubMed ID: 6514014
    [Abstract] [Full Text] [Related]

  • 2. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
    Claustre Y, Fage D, Zivkovic B, Scatton B.
    J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
    [Abstract] [Full Text] [Related]

  • 3. Effects of isomers of hydroxyaporphines on dopamine metabolism in rat brain regions.
    Baldessarini RJ, Marsh ER, Kula NS, Zong RS, Gao YG, Neumeyer JL.
    Biochem Pharmacol; 1990 Aug 01; 40(3):417-23. PubMed ID: 2383279
    [Abstract] [Full Text] [Related]

  • 4. Formation of deaminated metabolites of dopamine in noradrenaline neurons.
    Andén NE, Grabowska-Andén M.
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep 01; 324(1):1-6. PubMed ID: 6633676
    [Abstract] [Full Text] [Related]

  • 5. Delayed inhibition of dopamine synthesis by gamma-butyrolactone and baclofen: dopamine autoreceptor supersensitivity?
    Argiolas A, Fadda F, Melis MR, Marcou M, Porceddu ML, Gessa GL.
    Eur J Pharmacol; 1982 Nov 05; 85(1):23-7. PubMed ID: 6818043
    [Abstract] [Full Text] [Related]

  • 6. Apomorphine-haloperidol interactions: different types of antagonism in cortical and subcortical brain regions.
    Bacopoulos NG, Roth RH.
    Brain Res; 1981 Feb 02; 205(2):313-9. PubMed ID: 7470869
    [Abstract] [Full Text] [Related]

  • 7. Effect of yohimbine on brain monoamines: an in vivo study.
    Brannan T, Martinez-Tica J, Yahr MD.
    J Neural Transm Park Dis Dement Sect; 1991 Feb 02; 3(2):81-7. PubMed ID: 1716906
    [Abstract] [Full Text] [Related]

  • 8. Alteration of striatal dopaminergic functions implicated in methamphetamine-induced reverse tolerance in rats.
    Kaneno S, Watanabe A, Takahashi R.
    Eur J Pharmacol; 1986 Apr 16; 123(2):287-94. PubMed ID: 3086109
    [Abstract] [Full Text] [Related]

  • 9. The effect of phencyclidine on dopamine synthesis and metabolic in rat striatum.
    Doherty JD, Simonovic M, So R, Meltzer HY.
    Eur J Pharmacol; 1980 Jul 25; 65(2-3):139-49. PubMed ID: 7398783
    [Abstract] [Full Text] [Related]

  • 10. Developmental change in striatal concentration of homovanillic acid and 3,4-dihydroxyphenylacetic acid in response to apomorphine and haloperidol treatment.
    Nomura Y, Komori T, Okuda S, Segawa T.
    Arch Int Pharmacodyn Ther; 1979 Jan 25; 237(1):25-30. PubMed ID: 485682
    [Abstract] [Full Text] [Related]

  • 11. Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo.
    Galloway MP, Wolf ME, Roth RH.
    J Pharmacol Exp Ther; 1986 Mar 25; 236(3):689-98. PubMed ID: 3081705
    [Abstract] [Full Text] [Related]

  • 12. The D1 agonist SKF 38393 increases dopamine release in the developing rat striatum.
    Walters DE, Howard SG.
    Eur J Pharmacol; 1990 Aug 10; 184(2-3):257-64. PubMed ID: 2150376
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.
    Martin GE, Haubrich DR, Williams M.
    Eur J Pharmacol; 1981 Nov 19; 76(1):15-23. PubMed ID: 7318920
    [Abstract] [Full Text] [Related]

  • 14. Kinetics of drug-induced changes in dopamine and serotonin metabolite concentrations in the CSF of the rat.
    Mignot E, Laude D, Elghozi JL.
    J Neurochem; 1984 Mar 19; 42(3):819-25. PubMed ID: 6198472
    [Abstract] [Full Text] [Related]

  • 15. A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity.
    Feenstra MG, Sumners C, Goedemoed JH, de Vries JB, Rollema H, Horn AS.
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep 19; 324(2):108-15. PubMed ID: 6646238
    [Abstract] [Full Text] [Related]

  • 16. In vivo dopamine autoreceptor selectivity appears to be critically dependent upon the aromatic hydroxyl position in a series of N,N-disubstituted 2-aminotetralins.
    Van Oene JC, De Vries JB, Dijkstra D, Renkema RJ, Tepper PG, Horn AS.
    Eur J Pharmacol; 1984 Jun 15; 102(1):101-15. PubMed ID: 6434327
    [Abstract] [Full Text] [Related]

  • 17. Antidopaminergic properties of yohimbine.
    Scatton B, Zivkovic B, Dedek J.
    J Pharmacol Exp Ther; 1980 Nov 15; 215(2):494-9. PubMed ID: 7192314
    [Abstract] [Full Text] [Related]

  • 18. On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain.
    Westerink BH, Spaan SJ.
    J Neurochem; 1982 Mar 15; 38(3):680-6. PubMed ID: 7057187
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the effects of dopamine D1 and D2 receptor antagonists on rat striatal, limbic and nigral dopamine synthesis and utilisation.
    Magnusson O, Mohringe B, Fowler CJ.
    J Neural Transm; 1987 Mar 15; 69(3-4):163-77. PubMed ID: 2957465
    [Abstract] [Full Text] [Related]

  • 20. Effects of neurotransmitters or drugs on the in vivo release of dopamine and its metabolites.
    Kito S, Shimoyama M, Arakawa R.
    Jpn J Pharmacol; 1986 Jan 15; 40(1):57-67. PubMed ID: 2870204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.